Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer - Episode 1

Introduction and HR+/HER2– eBC Overview

,

Panelists discuss how HR+/HER2– early-stage breast cancer (eBC) is characterized by hormone receptor–positive, HER2-negative tumors, focusing on unmet patient needs, the goals of treatment in this setting, and the critical timing for discussing recurrence risk with patients.

Now Viewing
EP. 1: Introduction and HR+/HER2– eBC Overview
EP. 2: Approaches to eBC Diagnosis and Risk Stratification
EP. 3: CDK4/6 Inhibitors Treatment Options in the eBC Setting
EP. 4: Clinical Trial Considerations for eBC Treatment Selection
EP. 5: Clinical Decision-Making for a Patient With eBC: Scenario and Strategies
EP. 6: Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence

Video content above is prompted by the following:

  • Please provide an overview of HR+/HER2– early-stage breast cancer (eBC). (Patient population, disease presentation, etc.)
    • What are unmet needs for these patients?
    • What are your goals in the eBC setting?
  • When do you talk to patients about the risk of recurrence?

Related Content:

Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer
Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence
Clinical Decision-Making for a Patient With eBC: Scenario and Strategies
Clinical Trial Considerations for eBC Treatment Selection